Want to see TSE:FRX full AI Analyst Report?
FRX Stock Chart & Stats
C$13.95
-C$0.70(-4.78%)
At close: 4:00 PM EDT
C$13.95
-C$0.70(-4.78%)
Day’s Range― - ―
52-Week RangeC$7.59 - C$18.50
Previous CloseN/A
Volume1.00
Average Volume (3M)639.00
Market Cap
C$545.27M
Enterprise ValueC$350.37
Total Cash (Recent Filing)C$41.25M
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Nov 05, 2026EPS Estimate
0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding35,067,158
10 Day Avg. Volume82
30 Day Avg. Volume639
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)6.28
Price to Sales (P/S)4.93
P/FCF Ratio-17.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$24.96Price Target Upside78.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.36
Revenue Forecast (FY)C$94.15M
Bulls Say, Bears Say
Bulls Say
PEDMARK Commercial GrowthSustained sales growth and rising infusions, enrollments and active patients indicate expanding PEDMARK adoption. Broader prescriber coverage and stronger site penetration can support durable revenue growth as commercialization matures.
High-margin Product EconomicsThe exceptionally high gross margin provides substantial contribution potential from incremental PEDMARK sales. This creates operating leverage as commercial scale improves, although the company still needs disciplined spending to convert gross profit into durable earnings.
Debt-free Balance SheetA debt-free structure and rebuilt positive equity reduce financing risk and preserve flexibility for commercialization and evidence generation. The cash position, together with projected PEDMARK revenue, supports the current operating plan without stated dependence on debt funding.
Bears Say
Negative Cash GenerationDespite improving from 2025, the business is not yet consistently self-funding. Continued negative and volatile cash flow could constrain investment or require external financing if PEDMARK growth, collections or operating leverage fall short.
Profitability Remains UnprovenPositive adjusted EBITDA in Q2 is encouraging, but GAAP profitability has not been consistent and commercial expansion is increasing SG&A. The company must sustain revenue growth and control spending before earnings quality can be considered durable.
Product And Indication ConcentrationPEDMARK is the core commercial product and sales are concentrated in three tumor types, increasing exposure to changes in treatment patterns or adoption. Diversification depends on clinical evidence, guideline upgrades and possible label expansion that remain uncertain.
Fennec Pharmaceuticals News
FRX FAQ
What was Fennec Pharmaceuticals’s price range in the past 12 months?
Fennec Pharmaceuticals lowest stock price was C$7.59 and its highest was C$18.50 in the past 12 months.
What is Fennec Pharmaceuticals’s market cap?
Fennec Pharmaceuticals’s market cap is C$545.27M.
When is Fennec Pharmaceuticals’s upcoming earnings report date?
Fennec Pharmaceuticals’s upcoming earnings report date is Nov 05, 2026 which is in 73 days.
How were Fennec Pharmaceuticals’s earnings last quarter?
Fennec Pharmaceuticals released its earnings results on Aug 11, 2026. The company reported C$0.069 earnings per share for the quarter, beating the consensus estimate of C$0.028 by C$0.042.
Is Fennec Pharmaceuticals overvalued?
According to Wall Street analysts Fennec Pharmaceuticals’s price is currently Undervalued.
Does Fennec Pharmaceuticals pay dividends?
Fennec Pharmaceuticals does not currently pay dividends.
What is Fennec Pharmaceuticals’s EPS estimate?
Fennec Pharmaceuticals’s EPS estimate is 0.14.
How many shares outstanding does Fennec Pharmaceuticals have?
Fennec Pharmaceuticals has 35,067,158 shares outstanding.
What happened to Fennec Pharmaceuticals’s price movement after its last earnings report?
Fennec Pharmaceuticals reported an EPS of C$0.069 in its last earnings report, beating expectations of C$0.028. Following the earnings report the stock price went up 15.38%.
Which hedge fund is a major shareholder of Fennec Pharmaceuticals?
Currently, no hedge funds are holding shares in TSE:FRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fennec Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$24.96 (78.92% Upside)
C$24.96 (78.92% Upside)
Blogger Sentiment
Neutral
TSE:FRX Sentiment 50%
Sector Average 61%
Sector Average 61%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.1%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
18.30%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
68.81%
Trailing 12-Months
Company Description
Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.
FRX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial and clinical momentum: double-digit and sequential revenue growth (+78% YoY in Q2), return to positive adjusted EBITDA, record operational metrics in July, expanded commercial reach and multiple ISTs with notable forthcoming data (SIOP oral presentation). These positives are tempered by higher SG&A and marketing-driven OpEx, short-term cash timing volatility, reliance on a concentrated set of tumor types for the majority of sales, and the need for additional clinical data to drive guideline upgrades and label expansion. Management is bullish on continued growth but remains conservative on formal revenue guidance until further traction and data maturity are achieved.View all TSE:FRX earnings summariesFRX Stock 12 Month Forecast
Average Price Target
C$24.96
▲(78.92% Upside)
Technical Analysis
Satellos Bioscience
―
Helix BioPharma
―
―
Eupraxia Pharmaceuticals
―
ME Therapeutics Holdings, Inc.
―